21:51 , Mar 7, 2019 |  BC Extra  |  Financial News

Follow-on roundup: Horizon, Apellis, Epizyme

Horizon, Apellis and Epizyme each priced follow-ons raising a total of $552 million. Horizon Pharma plc (NASDAQ:HZNP) raised $300 million late Wednesday through the sale of 12 million shares at $24.50. The price is a...
20:04 , Feb 4, 2019 |  BC Extra  |  Company News

Management tracks: PhRMA, Amgen, Apellis

Sanofi (NASDAQ:SNY; Euronext:SAN) CEO Olivier Brandicourt became chairman of PhRMA. Brandicourt was chairman-elect and succeeds Robert Bradway, who is chairman and CEO of Amgen Inc. (NASDAQ:AMGN). PhRMA named Giovanni Caforio chairman-elect. Caforio is chairman and...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
23:31 , Dec 21, 2018 |  BC Extra  |  Company News

Alexion gains early approval for long-acting PNH therapy

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) received FDA approval for Ultomiris ravulizumab-cwvz (ALXN1210), the biotech's long-acting formulation of Soliris eculizumab, to treat paroxysmal nocturnal hemoglobinuria. While the approval came nearly two months ahead of the Feb. 18...
18:34 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

Apellis pauses Phase III trials after single lot of APL-2 causes inflammation

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) voluntarily paused dosing in Phase III trials of intravitreal APL-2 to treat geographic atrophy due to eight reported cases of non-infectious inflammation in patients treated from a single manufacturing lot of...
18:48 , Oct 18, 2018 |  BC Extra  |  Clinical News

Apellis pauses Phase III trials after single lot of APL-2 causes inflammation

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) lost $2.85 (17%) to $13.86 on Thursday after it voluntarily paused dosing in Phase III trials of intravitreal APL-2 to treat geographic atrophy due to eight reported cases of non-infectious inflammation...
19:36 , Apr 20, 2018 |  Completed Offerings  |  Completed Offerings

Apellis raises $140.3M in follow-on

Autoimmune company Apellis Pharmaceuticals Inc. (NASDAQ:APLS) raised $140.3 million late on April 18 through the sale of 5.5 million shares at $25.50 in a follow-on underwritten by Citigroup, J.P. Morgan and Cowen. The price is...
17:58 , Apr 20, 2018 |  Clinical Results  |  Clinical Results

Apellis reports additional Phase Ib data for C3 inhibitor in PNH

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported data from eight evaluable patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received Soliris eculizumab in the open-label, New Zealand Phase Ib PADDOCK trial showing that once-daily 270...
20:27 , Apr 19, 2018 |  BC Extra  |  Financial News

Apellis raises $140.3M in follow-on

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) raised $140.3 million late Wednesday through the sale of 5.5 million shares at $25.50 in a follow-on underwritten by Citigroup, J.P. Morgan and Cowen. The price is a 15% discount to...
20:35 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Apellis reports 18-month Phase II data for GA candidate

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported 18-month data from the Phase II FILLY trial to treat geographic atrophy showing that APL-2 for 12 months maintained significant reductions in lesion growth at six months after stopping treatment....